Objective: To determine the frequency and cardia, gastroesophageal junction and gastric expression of HER2/neu positivity by immuno- fundus was found to be 6 (14.3%), 6 (37.5%) and histochemistry in gastric adenocarcinoma. 2 (20%), respectively. 36 (52.9%) cases were Methodology: A total of 68 cases of gastric intestinal-type and 32 (47.1%) were signet ring adenocarcinoma were included and type and 3+ HER2/neu staining was 12 (33.3%), Immunohistochemical marker for HER2/neu was and 2 (6.3%), respectively. There were 3+ applied and evaluated on paraffin sections. positive in 14 (20.6%) cases, 0, 1+ negative in 38 HER2/neu overexpression according to age, (55.9%) cases and 2+ equivocal in 16 (23.5%). gender, site and histological type was determined. Conclusion: HER2/neu overexpression can be HER2/neu was assessed on the membrane determined in gastric adenocarcinoma by using staining of tumor cells. It was considered positive immunohistochemistry. Approximately 21% cases when more than 10% of the cells stained positively showed overexpression in our study. Larger in resection specimens and for biopsy specimens studies are required for more definitive results to at least 5 cells were positive. accurately determine proportion of patients who Results: Out of 68 cases, 42 (61.8%) were may benefit from trastuzumab therapy. (Rawal gastric cardia in origin , 1 6 ( 2 3 . 5 % ) o f Med J 202;45:537-540). gastoesophageal junction and 10 (14.7%) ofgastric fundus. 3+ HER2/neu staining in gastric cardia, gastroesophageal junction and gastric fundus was found to be 6 (14.3%), 6 (37.5%) and 2 (20%), respectively. 36 (52.9%) cases were intestinal type and 32 (47.1%) were signet ring type and 3+ HER2/neu staining was 12 (33.3%), and 2 (6.3%), respectively. There were 3+ positive in 14 (20.6%) cases, 0, 1+ negative in 38 (55.9%) cases and 2+ equivocal in 16 (23.5%).Conclusion: HER2/neu overexpression can be determined in gastric adenocarcinoma by using immunohistochemistry. Approximately 21% cases showed overexpression in our study. Larger studies are required for more definitive results to accurately determine proportion of patients who may benefit from trastuzumab therapy.